Sodium Taurochenodeoxycholate (Highly Pure)

Sodium Taurochenodeoxycholate (Highly Pure)
Catalog number: B2010634
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 25 mg
Molecular Weight or Concentration: 521.69 g/mol
Supplied as: Powder
Applications: highly effective detergent in solubilizing lipids and proteins
Storage: RT
Keywords: 3α,7α-Dihydroxy-5β-cholan-24-oic acid N-(2-sulfoethyl)amide sodium salt, Taurochenodeoxycholic acid sodium salt, 2-([3α,7α-Dihydroxy-24-oxo-5β-cholan-24-yl]amino)ethanesulfonic acid sodium salt
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, Karam C,
Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson
T, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S,
Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal
NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Dickson SP, Ellison N,
Hall M, Hendrix K, Kittle G, McGovern M, Ostrow J, Pothier L, Randall R, Shefner
JM, Sherman AV, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J,
Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D,
Cudkowicz ME. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic
Lateral Sclerosis. N Engl J Med. 2020 Sep 3;383(10):919-930.

2: Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, Elliott
MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA,
Heitzman D, Heiman-Patterson TD, Jackson CE, Quinn C, Rothstein JD, Kasarskis
EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass
JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M,
Dagostino D, Hall M, Kittle G, Eydinov M, McGovern M, Ostrow J, Pothier L,
Randall R, Shefner JM, Sherman AV, St Pierre ME, Tustison E, Vigneswaran P,
Walker J, Yu H, Chan J, Wittes J, Yu ZF, Cohen J, Klee J, Leslie K, Tanzi RE,
Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Long-term survival of
participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in
amyotrophic lateral sclerosis. Muscle Nerve. 2021 Jan;63(1):31-39.

3: Cohen BI, Raicht RF, Mosbach EH. Sterol metabolism studies in the rat.
Effects of primary bile acids (sodium taurochenodeoxycholate and sodium
taurocholate) on sterol metabolism. J Lipid Res. 1977 Mar;18(2):223-31.

4: Häussinger D, Kordes C. Mechanisms of Tauroursodeoxycholate-Mediated
Hepatoprotection. Dig Dis. 2017;35(3):224-231.

5: Raicht RF, Cohen BI, Mosbach EH. Effects of sodium taurochenodeoxycholate and
sodium taurocholate on cholesterol absorption in the rat. Gastroenterology. 1974
Dec;67(6):1155-61.

6: Krupa Ł, Staroń R, Dulko D, Łozińska N, Mackie AR, Rigby NM, Macierzanka A,
Markiewicz A, Jungnickel C. Importance of Bile Composition for Diagnosis of
Biliary Obstructions. Molecules. 2021 Nov 30;26(23):7279.

7: Javitt NB, Emerman S. Effect of sodium taurolithocholate on bile flow and
bile acid exeretion. J Clin Invest. 1968 May;47(5):1002-14.
8: Accatino L, Figueroa C, Pizarro M, Solís N. Enhanced biliary excretion of
canalicular membrane enzymes in estrogen-induced and obstructive cholestasis,
and effects of different bile acids in the isolated perfused rat liver. J
Hepatol. 1995 Jun;22(6):658-70.

9: Zhang X, Han Y, Huang W, Jin M, Gao Z. The influence of the gut microbiota on
the bioavailability of oral drugs. Acta Pharm Sin B. 2021 Jul;11(7):1789-1812.
10: Fuchs A, Leigh M, Kloefer B, Dressman JB. Advances in the design of fasted
state simulating intestinal fluids: FaSSIF-V3. Eur J Pharm Biopharm. 2015
Aug;94:229-40.

Products Related to Sodium Taurochenodeoxycholate (Highly Pure): Chemicals